Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection

Journal of Clinical Virology

Volumn 55, Issue 2, 2012, Pages 107-113

  Nicot, F ^a   Saliou, A ^a,b   Raymond, S ^a,b,c   Saune K ^a,b,c   Dubois, M ^a,b   Massip, P ^a   Marchou, B ^a   Delobel, P ^a,b,c   Izopet, J ^a,b,c  

^a CHU PURPAN   (France)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

E138 mutation; Minority mutation; Primary infection; Pyrosequencing; Rilpivirine

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; COPY NUMBER VARIATION; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RESISTANCE ASSOCIATED MUTATION; PRIMARY INFECTION; PRIORITY JOURNAL; PYROSEQUENCING;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 84865193368     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.06.018     Document Type: Article

References (35)

1. Vercauteren J., Wensing A.M., van de Vijver D.A., Albert J., Balotta C., Hamouda O., et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009, 200:1503-1508.
2. Chaix M.L., Descamps D., Wirden M., Bocket L., Delaugerre C., Tamalet C., et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009, 23:717-724.
3. Halvas E.K., Aldrovandi G.M., Balfe P., Beck I.A., Boltz V.F., Coffin J.M., et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006, 44:2612-2614.
4. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47:266-285.
5. Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Allers K., Joos B., et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003, 188:1433-1443.
6. Paredes R., Marconi V.C., Campbell T.B., Kuritzkes D.R. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 2007, 146:136-146.
7. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009, 199:693-701.
8. St John E.P., Simen B., Turenchalk G.S., Braverman M.S., Abbate I., Aerssens J., et al. A follow-up multicenter collaborative study on HIV-1 drug resistance and tropism testing using 454 massively parallel pyrosequencing. International workshop on HIV and hepatitis virus drug resistance and curative strategies 2011, A81.
9. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007, 17:1195-1201.
10. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Metzner K.J., Kozal M.J., et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
11. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.
12. Zhang Z., Hamatake R., Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 2004, 15:121-134.
13. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:39-48.
14. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
15. Wilkin A., Pozniak A.L., Morales-Ramirez J., Lupo S.H., Santoscoy M., Grinsztejn B., et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 2012, 28(5):437-446.
16. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237.
17. Molina J.M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378:238-246.
18. Azijn H., Tirry I., Vingerhoets J., de Bethune M.P., Kraus G., Boven K., et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010, 54:718-727.
19. Rimsky L., Vingerhoets J., Van Eygen V., Eron J., Clotet B., Hoogstoel A., et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012, 59:39-46.
20. Jakobsen M.R., Tolstrup M., Sogaard O.S., Jorgensen L.B., Gorry P.R., Laursen A., et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010, 50:566-573.
21. Stekler J.D., Ellis G.M., Carlsson J., Eilers B., Holte S., Maenza J., et al. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One 2011, 6:e28952.
22. Johnson V.A., Calvez V., Gunthard H.F., Paredes R., Pillay D., Shafer R., et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011, 19:156-164.
23. Lataillade M., Chiarella J., Yang R., Schnittman S., Wirtz V., Uy J., et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 2010, 5:e10952.
24. Tambuyzer L., Azijn H., Rimsky L.T., Vingerhoets J., Lecocq P., Kraus G., et al. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009, 14:103-109.
25. Varghese V., Shahriar R., Rhee S.Y., Liu T., Simen B.B., Egholm M., et al. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009, 52:309-315.
26. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005, 2:e112.
27. Halvas E.K., Wiegand A., Boltz V.F., Kearney M., Nissley D., Wantman M., et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010, 201:672-680.
28. Metzner K.J., Rauch P., Walter H., Boesecke C., Zollner B., Jessen H., et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005, 19:1819-1825.
29. Paredes R., Lalama C.M., Ribaudo H.J., Schackman B.R., Shikuma C., Giguel F., et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010, 201:662-671.
30. Li J.Z., Paredes R., Ribaudo H.J., Svarovskaia E.S., Kozal M.J., Hullsiek K.H., et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012, 26:185-192.
31. Gianella S., Delport W., Pacold M.E., Young J.A., Choi J.Y., Little S.J., et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011, 85:8359-8367.
32. Goodman D.D., Zhou Y., Margot N.A., McColl D.J., Zhong L., Borroto-Esoda K., et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011, 25:325-333.
33. Delobel P., Saliou A., Nicot F., Dubois M., Trancart S., Tangre P., et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One 2011, 6:e21655.
34. Tambuyzer L., Nijs S., Daems B., Picchio G., Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr 2011, 58:18-22.
35. Asahchop E.L., Oliveira M., Wainberg M.A., Brenner B.G., Moisi D., Toni T., et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011, 55:600-607.